SecBot SecBot
PRESS-RELEASE ·Filed Mar 24, 2026

BNTX

BioNTech SE
BULLISH
Impact 8/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight ▲ Bullish

Monitor progression of pivotal Phase 3 trials, especially top-line results from PRESERVE-003 and ROSETTA Lung-01/02. The 54% survival benefit with gotistobart is a strong signal; confirmatory data could drive significant valuation upside. Combination trials may unlock additional market potential.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$86.81
T+0 close · Mar 24, 2026 · via day close
Latest settled
+4.70%
T+60 · $90.89
Vs SPY
−9.62%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 24 $86.81entry
  2. T+1 · 8mo ago +2.26%α +1.69% · $88.77
  3. T+5 · 8mo ago +2.38%α +2.81% · $88.88
  4. T+20 · 7mo ago +25.10%α +16.20% · $108.60
  5. T+60 · 5mo ago +4.70%α −9.62% · $90.89
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioNTech presented new clinical data from its late-stage lung cancer programs at the European Lung Cancer Congress 2026, highlighting promising results for pumitamig and gotistobart. Gotistobart showed a 54% reduction in risk of death in squamous NSCLC, while pumitamig and the HER3-targeted ADC BNT326/YL202 demonstrated encouraging antitumor activity and manageable safety profiles across multiple lung cancer subtypes.

Key Facts

  • Gotistobart showed a 54% reduction in risk of death vs. standard of care in 2L+ squamous NSCLC in stage 1 of the Phase 3 PRESERVE-003 trial.
  • Pumitamig demonstrated clinically meaningful survival outcomes in EGFR-mutant NSCLC and encouraging activity in ES-SCLC and NSCLC regardless of PD-L1 status.
  • First clinical data for BNT326/YL202, a HER3-targeted ADC, showed antitumor activity and favorable safety in advanced NSCLC.
  • Data support ongoing pivotal Phase 3 trials ROSETTA Lung-01 (ES-SCLC) and ROSETTA Lung-02 (NSCLC), and a novel combination trial of pumitamig + BNT326/YL202.
  • Presentations cover 16 ongoing lung cancer trials, including four pivotal Phase 3 studies.

Financial Impact

Potential multibillion-dollar commercial opportunity if pivotal trials confirm efficacy, particularly in high-prevalence lung cancer indications.

revenuepipeline valuemarket cap

Risk Factors

  • Stage 1 data for gotistobart is non-pivotal; results may not be replicated in larger, randomized cohorts.
  • All candidates are still in development with no guaranteed regulatory approval.
  • Competition in lung cancer immunotherapy and ADC space is intense, with multiple established and emerging therapies.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3261033

Track record

38 reports on BNTX

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +24.37% at T+60 after the May 30, 2026 report. 10 of 15 went positive at some point.

Filters
  1. Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.26 −2.24% settles Feb 8
  2. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  3. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  4. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.26 −1.91% settles Feb 1
  5. Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.26 −4.34% settles Jan 27
  6. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
  7. Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
  8. Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
  9. Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
  10. Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.26 −4.92% settles Jan 20
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (14h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 24, 2026